1888305-96-1 Usage
Description
4-(2-bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide is a complex organic compound characterized by the presence of a pyrrole ring with a carboxamide group, a benzoyl group substituted with bromine and fluorine, and a pyridine ring. Its unique structure and properties suggest potential applications in various fields, particularly in pharmaceuticals and materials science. However, further research is required to explore and confirm its specific uses and effects.
Uses
Used in Pharmaceutical Industry:
4-(2-bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide is used as a potential pharmaceutical compound for its unique chemical structure and properties. The presence of different functional groups, such as the pyrrole ring, carboxamide, benzoyl group with halogen substituents, and the pyridine ring, may contribute to its potential therapeutic effects and interactions with biological targets.
Used in Materials Science:
In the field of materials science, 4-(2-bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide may be utilized for the development of novel materials with specific properties. The combination of different functional groups in its structure could potentially lead to the creation of materials with unique characteristics, such as improved stability, reactivity, or selectivity in various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1888305-96-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,8,8,3,0 and 5 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1888305-96:
(9*1)+(8*8)+(7*8)+(6*8)+(5*3)+(4*0)+(3*5)+(2*9)+(1*6)=231
231 % 10 = 1
So 1888305-96-1 is a valid CAS Registry Number.
1888305-96-1Relevant articles and documents
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4
Myers, Stephanie M.,Miller, Duncan C.,Molyneux, Lauren,Arasta, Mercedes,Bawn, Ruth H.,Blackburn, Timothy J.,Cook, Simon J.,Edwards, Noel,Endicott, Jane A.,Golding, Bernard T.,Griffin, Roger J.,Hammonds, Tim,Hardcastle, Ian R.,Harnor, Suzannah J.,Heptinstall, Amy B.,Lochhead, Pamela A.,Martin, Mathew P.,Martin, Nick C.,Newell, David R.,Owen, Paul J.,Pang, Leon C.,Reuillon, Tristan,Rigoreau, Laurent J.M.,Thomas, Huw D.,Tucker, Julie A.,Wang, Lan-Zhen,Wong, Ai-Ching,Noble, Martin E.M.,Wedge, Stephen R.,Cano, Celine
, p. 530 - 543 (2019/06/19)
Extracellular regulated kinase 5 (ERK5) signalling has been implicated in driving a number of cellular phenotypes including endothelial cell angiogenesis and tumour cell motility. Novel ERK5 inhibitors were identified using high throughput screening, with
